Join us at the 8th Antigen Specific Immune Tolerance Summit
Building on the success of last year’s meeting, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases.
With major pharmaceutical companies like Pfizer, GSK, Sanofi, and Boehringer Ingelheim showing increasing interest, the market for antigen-specific immune tolerance therapies is poised for significant growth. Recent partnerships and investments, such as COUR's $105 million Series A financing and Cartesian's acquisition of Selecta Biosciences, underscore the immense potential of these therapies to revolutionize the inflammation and immunology sector.
New for 2024:
- New antigens and disease targets: hear COUR Pharmaceutical’s brand-new data read out from their phase 2 clinical trial Primary Biliary Cholangitis, a never-before-seen disease at the ASIT Summit
- Antigen Discovery & Selection Seminar Day: Join this interactive seminar day to get ahead of the curve in novel technologies being developed for antigen discovery and selection to inform your next disease target
- Large Pharma and Venture Capital Perspectives Panel: Growing on the success of last year's panel, hear insights on search & evaluation strategies from AbbVie & Lilly, investment priorities from immunology venture studio ARGOBIO, and Cue Biopharma’s experience in developing partner programs in immune tolerance to put your company in the best stead for future scientific and commercial opportunities
Join Your Peers to:
Delineate brand-new data on the long-term efficacy, durability, and safety of antigen-specific therapies to further understand their viability as a therapeutic product and take away actionable insights to turbocharge your therapeutic development with Immunocore and Parvus Therapeutics
Dig deep into antigen selection for complex, heterogeneous autoimmune diseases to kickstart the expansion of ASIT therapies to larger patient populations and increase market share with Pfizer, AbbVie, and the Karolinska Institutet
Evaluate the biomarkers of tolerance that correlate with specific disease endpoints and biomarkers to inform clinical endpoints and strive towards standardized biomarkers of tolerance to avoid bottlenecks in translational development with the Immune Tolerance Network, Toleranzia, and PolTREG
Optimize drug development through the analysis of the latest clinical data from COUR Pharmaceuticals, Diamyd, and Annokion to inform clinical strategy, improve efficacy, and expedite the development of new therapies for T1D, Myasthenia Gravis, and Multiple Sclerosis
Uncovering next-generation mechanisms of actions and platform delivery technologies including CAR-T & mRNA approaches to advance specific, targeted approaches for inducing immune tolerance with Moderna, Genti Bio, and Integrated Nanotherapeutics
Who Will You Meet?
120+ senior decision makers from C-Level to senior scientists from leading immune tolerance, immunology, and autoimmune disease-focused big pharma and smaller biotech will unite in Boston. Across discovery, research, translation, biomarker development, clinical, search & evaluations, and business development, end-to-end colleagues will unite in one room to advance curative therapies for autoimmune patients in need.
What Your Peers Have To Say:
‘Excellent content. Excellent possibilities to discuss with peers.’
CEO, Amarna Therapeutics
'Excellent presentations. Lots of great speakers.’
IP & Business Analyst, COUR Pharmaceuticals
‘Good overview over the most exciting area for therapy development in autoimmunity just now’
Professor, Karolinska Institutet
‘Friendly environment, focused discussion and participants willing to share their experiences’
Senior Principal Scientist – Immunology, Bristol Myers Squibb
‘ASIT was very diverse, encompassing different technology to cure the unwanted immunity.’
Senior Scientist, GRO Bio
